Vaccines for GAVI
Pfizer and GlaxoSmithKline have entered into separate agreements with the GAVI Alliance to supply pneumococcal vaccines to developing countries. Each company has agreed to supply as many as 480 million doses of their pneumococcal vaccinesRead more at http://www.PharmTech.com/gavivaccines
BMS acquires Inhibitex
In a deal worth almost €2 billion, Bristol-Myers Squibb has commenced a cash tender offer to purchase all outstanding shares of Inhibitex. The transaction will provide BMS with an oral nucleotide polymerase inhibitor that is currently in Phase II development for the treatment of hepatitis C.
Read more at http://www.PharmTech.com/bmsdeal
Sanofi boosts start-up
Sanofi is extending a helping hand to start-up biotech company Warp Drive Bio by providing funding, access to its strains library and expertise in natural products. Two US venture capitalist firms will also invest in the start up, with all three offering funding that could amount during $125 million in the next five years.
Read more at http://www.PharmTech.com/sanofiboost
Ranbaxy's consent decree
Pledging to strengthen procedures and policies to ensure data integrity and comply with cGMP, Ranbaxy has signed a consent decree with the FDA. The company will also make a provision of $500 million to resolve liability in connection with an investigation by the US Department of Justice.
Read more at http://www.PharmTech.com/ranbaxy